Article

Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.

Pharmaceutical Discovery Division, SRI International, Menlo Park, CA 94025, USA.
European Journal of Pharmacology (impact factor: 2.52). 10/2001; 428(1):29-36. DOI:10.1016/S0014-2999(01)01282-1 pp.29-36
Source: PubMed

ABSTRACT Nociceptin/orphanin FQ (N/OFQ) was recently identified as the endogenous ligand for the opioid-receptor like (ORL1) receptor. Although the ORL1 receptor shows sequence homology with the opioid receptors, the nociceptin/ORL1 ligand-receptor system has very distinct pharmacological actions compared to the opioid receptor system. Recently, several small-molecule ORLI receptor ligands were reported by pharmaceutical companies. Most of these ligands had close structural similarities with known neuroleptics and opiates. In this study, we screened several available neuroleptics and opiates for their binding affinity and functional activity at ORL1 and the opioid receptors. We also synthesized several analogs of known opiates with modified piperidine N-substituents in order to characterize the ORL1 receptor ligand binding pocket. Substitution with the large, lipophilic cyclooctylmethyl moiety increased ORL1 receptor affinity and decreased mu receptor affinity and efficacy in the fentanyl series of ligands but had a different effect in the oripavine class of opiate ligands. Our results indicate that opiates and neuroleptics may be good starting points for ORL1 receptor ligand design, and the selectivity may be modulated by appropriate structural modifications.

0 0
 · 
0 Bookmarks
 · 
5 Views
  • Source
    Article: Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes.
    [show abstract] [hide abstract]
    ABSTRACT: Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. This review covers the evolution of research in this field over the last 25 years.
    Journal of Alzheimer's disease: JAD 10/2012; · 3.74 Impact Factor
  • Source
    Dataset: Froestl 2012 Part1
  • Source
    Dataset: Froestl 2012 Part1

Keywords

appropriate structural modifications
 
available neuroleptics
 
different effect
 
functional activity
 
lipophilic cyclooctylmethyl moiety
 
nociceptin/ORL1 ligand-receptor system
 
Nociceptin/orphanin FQ
 
opiate ligands
 
opioid receptor system
 
opioid receptors
 
opioid-receptor
 
oripavine class
 
ORL1 receptor
 
ORL1 receptor affinity
 
ORL1 receptor ligand binding pocket
 
ORL1 receptor ligand design
 
pharmaceutical companies
 
piperidine N-substituents
 
sequence homology
 
small-molecule ORLI receptor ligands